. Author manuscript; available in PMC: 2012 May 17.

Published in final edited form as: Curr Cancer Drug Targets. 2007 May;7(3):285–301. doi: 10.2174/156800907780618301

Table 2.

Prodrug armed Adenoviruses. Diverse strategies allow for the incorporation of prodrug-activating enzymes into treatment schemes to produce an improved anti-tumor combination therapy.

Adenovirus	Tumor- specificity	Mode of Action	Prodrug	Clinical Trial(s)	Ref
AdTK^RC	E1B-55 kDa	Oncolysis & suicide (TK) gene therapy	Ganciclovir	In vivo	[243]
Ad-5-CD-Tkrep or FGR	E1B-55 kDa	Oncolysis & suicide (CD & TK) gene therapy	5-Fluorocytosine & Ganciclovir	Phase I	[206]
ONYX-710→-713 (dl1520-CE)	E1B-55 kDa	Oncolysis & suicide (Carboxylesterase)	Irinotecan or CPT-11	In vivo	[244]
Onyx-015, CD/HSV-1, TK	E1B-55 kDa	Oncolysis & suicide (CD & TK) gene therapy	5-Fluorocytosine & Ganciclovir	In vitro	[206]